Home » Newsletters » BioWorld Science

BioWorld Science

May 8, 2002

View Archived Issues

Postoperative CAT-152 superior to 5-FU in preventing scarring after glaucoma filtration surgery

Sustained transcleral delivery of EYE-001 achieved using PLGA microspheres

Development of etomoxir delayed; lower doses to be tested

VEGF receptor kinase inhibitor normalizes retinal vascular leakage in diabetic rats

New strategic focus announced by NeoTherapeutics

Squalamine reported to have beneficial effects in animal model of wet AMD

Ketoprofen amides with selective activity against COX-2

Second-generation ETA antagonist in clinical development for heart failure

BIRB-796BS: structure, pharmacological activity described at recent meeting

FDA approves Bravelle for infertility

NDA submission for palonosetron for chemotherapy-induced nausea and vomiting on track

Small-molecule RXR modulators useful for type 2 diabetes

CT-3 shows antispastic activity in animal model of MS

Periostat approved in Israel

Avalox i.v. cleared for market introduction in Germany

Cathepsin inhibitors and potential therapeutic uses described by Boehringer Ingelheim

Novuspharma and Cephalon collaborate on proteasome inhibition-based cancer therapies

DT031I identified as potential target in inflammatory diseases

PhotoCure presents update of progress in the first quarter

P&G patents series for use in the treatment of cancer or viral infections

Melanocortin receptor ligands synthesized at Procter & Gamble

Bayer patent discloses adenosine uptake inhibitors and uses thereof

Neurogen presents carboxamide ligands of the benzodiazepine site of GABA-A receptors

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 28, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for April 28, 2026
Grace Therapeutics hits CRL setback with GTx-104 despite positive trial
BioWorld
Grace Therapeutics Inc.’s hopes of becoming the first company in decades to update the standard of care in aneurysmal subarachnoid hemorrhage were delayed after...
Neuro deals aplenty: UCB’s $1B+ takeover of Neurona the latest
BioWorld
A flurry of deals focused on the neurological disease space in 2026 suggest large biopharma companies are searching for the next best therapeutics for everything...
Plasticity, properly parsed, provides psychiatric platform
BioWorld
If Benjamin Braddock, of The Graduate fame, were a young neuroscientist in the 21st century instead of a liberal arts graduate in 1967, the advice he received...